top of page

Custom Probiotic Blends: How Supplement Brands Can Develop Unique Formulations

7 days ago
25 min read

The probiotic supplement market offers opportunities for brands seeking to develop differentiated products for digestive wellness, women's health, healthy ageing, general wellness, functional nutrition and other applications. However, creating a successful probiotic supplement involves more than combining several bacterial strains or increasing the declared colony-forming units (CFU).

A scientifically developed probiotic blend should have a clearly defined purpose, an appropriate selection of microorganisms, a documented formulation rationale, suitable manufacturing processes, validated or otherwise adequately supported stability, and specifications that can be maintained throughout the product's shelf life.

The scientific foundation is important. A systematic review and meta-analysis by McFarland and colleagues examined 228 clinical trials and identified evidence that probiotic efficacy can vary by strain and health condition. The authors emphasized the importance of evaluating specific microorganisms and indications rather than treating probiotics as a single interchangeable category [1].

Similarly, a systematic review comparing single-strain probiotics with multi-strain mixtures found that multi-strain products were not consistently more effective than single-strain products. Formulation decisions should therefore be guided by relevant evidence rather than simply the number of strains included [2].

For brands, the objective is to develop a formulation that is scientifically defensible, technically manufacturable, commercially viable and appropriate for its intended market.

This article explains how to develop custom probiotic blends, evaluate strains, design formulations, assess compatibility, establish quality specifications, investigate stability, review clinical evidence and select a suitable manufacturing partner.

What Is a Custom Probiotic Blend?

A custom probiotic blend is a formulation developed or adapted to meet defined product requirements rather than selected solely from a standard, ready-made ingredient catalogue.

Depending on the project, customization may involve:

  • Selecting specific probiotic strains.

  • Combining two or more microorganisms.

  • Establishing the proportion of each strain.

  • Defining the total viable count.

  • Selecting suitable carriers and excipients.

  • Combining probiotics with prebiotic ingredients.

  • Optimizing the formulation for capsules or sachets.

  • Establishing stability and packaging requirements.

  • Developing product-specific specifications.

  • Preparing technical documentation for the intended market.

A custom blend may contain a single microorganism selected for a specific formulation objective or multiple microorganisms chosen for a documented scientific and technical rationale.

The evidence-based review by Goodman and colleagues highlights the importance of considering strain selection, intended condition, dosage form, dose, manufacturing quality and shelf life when evaluating probiotic products [3].

For a supplement brand, custom formulation should therefore begin with a product brief rather than a predetermined list of microorganisms.

Standard blends versus custom blends

Parameter

Standard probiotic blend

Custom probiotic blend

Composition

Existing supplier formulation

Developed or adapted to customer requirements

Strain selection

Predetermined

Selected according to the project brief

Potency

Standard specification

Agreed project-specific specification

Dosage form

Limited to suitable existing applications

Evaluated for the intended dosage form

Packaging

Standard options

May be customized where technically feasible

Documentation

Standard product documentation

Standard documentation plus agreed project-specific information

Development time

Usually shorter

Depends on formulation complexity and testing

Minimum order quantity

Supplier-dependent

May be higher for complex or bespoke projects

Differentiation

Depends on the existing formulation and market

Potentially greater, if the formulation has meaningful technical or commercial distinctions

Custom formulation does not automatically create a more effective product. Its value lies in aligning the formulation with a defined objective and establishing suitable evidence, quality controls and manufacturing requirements.

Define the Product Concept Before Selecting Strains

One of the most important steps in probiotic formulation is defining the intended product before choosing the microorganisms.

Brands sometimes begin by asking for a blend containing five, eight or ten strains. However, selecting an arbitrary number of strains before defining the product objective can lead to unnecessary complexity.

A stronger approach starts with five questions.

Who is the intended consumer?

Define the intended consumer group and the product category.

Examples include:

  • Adults seeking everyday digestive wellness support.

  • Consumers interested in women's wellness products.

  • Adults seeking a daily nutritional supplement.

  • Consumers looking for probiotic and prebiotic combinations.

  • Individuals interested in age-specific nutritional products.

  • Consumers seeking convenient capsule or sachet formats.

The target group helps establish the product's dosage form, serving size, intended use and commercial positioning.

It does not, by itself, establish that a particular probiotic will produce a specific benefit. Such benefits require relevant evidence and compliant claims.

What is the intended product objective?

The objective should be described clearly enough to guide strain selection and product development.

For example, a brand may wish to develop a daily probiotic supplement with a defined viable count, convenient capsule format and room-temperature storage target.

Another brand may be developing a powder sachet containing probiotics and prebiotic fibres.

These projects have different formulation and stability considerations, even if both are marketed within the broader probiotic category.

Which dosage form will be used?

Decide whether the finished product will be a capsule, sachet, stick pack, tablet, powder, beverage or another suitable format.

The dosage form affects moisture exposure, oxygen exposure, manufacturing conditions, packaging requirements and consumer convenience.

A strain or blend that performs well in a dry capsule formulation may not be suitable for a beverage without additional evaluation.

Which countries will the product enter?

Define the intended markets at the beginning of development.

The regulatory status of ingredients, permissible claims, product classification, labeling requirements and documentation expectations can differ between countries.

A formulation intended for the United States may require a different regulatory review from one intended for the European Union, United Kingdom, India or Gulf region.

What is the commercial specification?

Establish the initial business requirements:

  • Target retail price.

  • Intended serving size.

  • Required CFU per serving.

  • Initial production volume.

  • Expected annual demand.

  • Packaging format.

  • Target shelf life.

  • Storage requirements.

  • Target launch date.

These requirements help determine whether a proposed formulation is technically and commercially feasible.

Lactobacillus paracasei probiotic powder for custom probiotic blends
Strain selection should rest on documented identity and relevant evidence, not species names alone.

Develop a Scientific Rationale for Strain Selection

Strain selection is one of the most consequential decisions in custom probiotic development.

Microorganisms within the same species may differ in their characteristics. Consequently, evidence supporting one strain should not automatically be transferred to another strain belonging to the same species.

McFarland and colleagues found evidence of both strain-specific and disease-specific effects in their systematic review and meta-analysis of probiotic clinical trials [1].

For formulation developers, this means that strain selection should be based on documented characteristics and relevant evidence rather than species names alone.

Identify the microorganism accurately

A technical strain specification should identify the microorganism as precisely as appropriate, including the strain designation.

For example, a specification that identifies only a bacterial species may be insufficient for a project requiring strain-specific scientific documentation.

Ask the prospective manufacturer:

  • What is the complete strain designation?

  • How is strain identity established?

  • Is the strain traceable to a recognized reference or authenticated culture?

  • What identity testing is performed?

  • Is the strain maintained under controlled conditions?

  • Can relevant technical documentation be supplied?

  • Has the organism undergone an appropriate safety assessment for its intended use?

The FAO/WHO-derived framework discussed by Binda and colleagues identifies adequate characterization, safety and appropriate evidence as important considerations when qualifying microorganisms as probiotics [4].

Review the scientific evidence

The next step is to examine whether the proposed strain has evidence relevant to the intended formulation.

Potential sources include:

  • Randomized controlled human trials.

  • Systematic reviews and meta-analyses.

  • Human observational research.

  • Laboratory studies.

  • Animal studies.

  • Safety assessments.

  • Mechanistic research.

These evidence types answer different questions.

Laboratory studies may provide information about biological mechanisms or technological characteristics. Animal studies may contribute to hypothesis development. Human clinical studies can provide evidence about outcomes in the populations studied.

However, results from one type of study should not be presented as equivalent to evidence from another.

The National Institutes of Health Office of Dietary Supplements explains that probiotic effects can be strain-specific and discusses the importance of considering the evidence for the specific probiotic under evaluation [5].

Evaluate the relevance of each publication

When reviewing a clinical study, examine:

  • The exact strain or formulation tested.

  • The study population.

  • The administered dose.

  • The duration of administration.

  • The comparator or control group.

  • The outcomes measured.

  • The statistical analysis.

  • The limitations reported by the authors.

A study involving a single-strain product may support further consideration of that strain. It does not automatically validate a different blend containing the same microorganism.

Similarly, evidence from a specific clinical population may not establish an equivalent result in a different population.

The practical guide by Goodman and colleagues provides an evidence-based approach to evaluating probiotic products according to the strain, indication, formulation, dose and product quality [3].

Create a strain-selection matrix

A strain-selection matrix helps formulation teams compare candidates systematically.

Selection criterion

Question to investigate

Identity

Is the strain precisely identified?

Safety

Is the safety information appropriate for the intended use?

Scientific evidence

What evidence supports the proposed application?

Dose

What dose has been studied, and in what formulation?

Stability

What is known about viability under relevant conditions?

Manufacturing suitability

Can the strain be blended and processed reliably?

Regulatory position

Is the strain suitable for the intended market and product category?

Supply continuity

Is the strain available with adequate traceability and supply planning?

Cost

Can the required specification be achieved within the target cost?

A scorecard should support informed decisions, not replace scientific judgment. Safety and regulatory requirements should be treated as mandatory gates rather than characteristics that can be offset by a low price.

Lactobacillus casei single-strain probiotic ingredient
Single-strain and multi-strain formulas each suit different product objectives.

Decide Whether to Develop a Single-Strain or Multi-Strain Product

A brand must decide whether its product should contain one microorganism or a combination.

Both approaches can be appropriate. The choice should be based on the intended formulation objective, available evidence, manufacturing requirements and commercial strategy.

When a single-strain formulation may be appropriate

A single-strain product may be attractive when:

  • Relevant evidence supports the selected strain.

  • The product has a narrowly defined formulation objective.

  • The strain can meet the required potency and stability specification.

  • A simpler composition makes quality control easier.

  • The brand wants a clear and straightforward product specification.

A single-strain formulation may also simplify strain identification and potency evaluation, although actual testing requirements depend on the product and analytical method.

When a multi-strain formulation may be appropriate

A multi-strain formulation may be considered when:

  • The product has a documented rationale for combining strains.

  • The individual microorganisms are suitable for the intended application.

  • The combined formulation can meet the required specifications.

  • Compatibility and stability can be adequately evaluated.

  • The complete product can be manufactured consistently.

However, adding strains increases formulation complexity. Different microorganisms may have different potency requirements, storage sensitivities or analytical characteristics.

A systematic review by McFarland found that, in most of the comparisons reviewed, multi-strain mixtures were not significantly more effective than single-strain products. The review therefore supports choosing products according to evidence for the relevant application rather than the number of strains [2].

A separate review examining the effectiveness of multi-strain versus single-strain probiotics also concluded that the assumption that more strains automatically produce better results lacks convincing supporting evidence [6].

Avoid arbitrary strain stacking

Strain stacking occurs when a formulation includes multiple microorganisms without a clear explanation of their respective roles.

It may increase ingredient cost, complicate testing and make it more difficult to establish which components are responsible for observed effects.

A more disciplined formulation process asks:

  • Why is each strain included?

  • What information supports its inclusion?

  • Is the strain compatible with the rest of the blend?

  • Can the final composition meet the specification?

  • Is the additional complexity justified?

The goal is not to maximize the strain count. It is to develop the most appropriate formulation for the defined objective.

Establish the Composition and Proportions of the Blend

After selecting candidate strains, the formulation team must establish the composition of the blend.

This involves deciding which strains to include, the amount of each ingredient, the intended potency, and any carriers or other formulation components.

Define the contribution of each strain

For each strain, document:

  • Strain designation.

  • Ingredient potency.

  • Intended contribution to the formulation.

  • Required amount in the blend.

  • Available evidence.

  • Relevant safety information.

  • Analytical requirements.

  • Stability considerations.

This documentation helps prevent the formulation from becoming an arbitrary mixture of ingredients.

Determine strain proportions

The proportions of individual strains should be established using a combination of scientific rationale, ingredient potency, technical requirements and cost.

A blend may use equal proportions by weight, but equal weight does not necessarily mean equal viable counts.

For example, two ingredients may have different CFU concentrations per gram. Adding equal masses of these ingredients can therefore produce different contributions to the total viable count.

Formulation calculations should use the potency and units specified for each ingredient.

Calculate the required ingredient quantities

For an ingredient with a known potency, the theoretical mass required to deliver a target number of CFU can be calculated using:

Required ingredient mass (g) = Target CFU Ă· Ingredient potency (CFU per g)

This is a mathematical illustration, not a recommended serving size or a clinical dose.

The actual formulation must account for the other ingredients, blending performance, analytical uncertainty, processing conditions and stability requirements.

Define the total blend potency

For a multi-strain blend, the total theoretical CFU contribution is the sum of the contributions from the individual ingredients, subject to the limitations of the available measurements.

The manufacturer should clearly state whether the specification represents:

  • Total viable count of the blend.

  • Individual strain counts.

  • Potency per gram.

  • Potency per serving.

  • Potency at batch release.

  • Minimum potency at the end of shelf life.

These distinctions are essential when translating a bulk ingredient specification into a finished-product specification.

Evaluate Compatibility Between Strains

A formulation that contains individually suitable microorganisms may still present technical challenges when the ingredients are combined.

Compatibility evaluation helps determine whether the selected strains can be blended, stored and processed together while maintaining the required product characteristics.

Consider differences in stability

Microorganisms may differ in their sensitivity to:

  • Moisture.

  • Oxygen.

  • Temperature.

  • Processing conditions.

  • Packaging conditions.

  • Storage duration.

A blend containing several ingredients must be evaluated as a formulation rather than assumed to behave like its most stable component.

Assess interactions between ingredients

Interactions may occur between the microorganisms themselves or between the microorganisms and the formulation's other ingredients.

Potential considerations include the carrier system, excipients, prebiotic ingredients, processing aids and packaging environment.

The existence of different organisms in a blend does not, by itself, establish that they will interact beneficially or negatively. Such conclusions require appropriate evidence.

Evaluate compatibility through development studies

Depending on the formulation, development work may include:

  • Initial potency assessment.

  • Blend uniformity testing.

  • Relevant microbiological testing.

  • Moisture-related evaluation.

  • Packaging compatibility.

  • Stability studies.

  • Pilot-scale manufacturing evaluation.

The tests should be selected according to the risks and specifications of the proposed product.

Do not assume synergy

Synergy is sometimes used in probiotic marketing to describe a combination expected to produce a greater effect than its individual components.

However, the term should not be used as an established scientific conclusion without appropriate supporting evidence.

A formulation team may have a reasonable hypothesis that particular strains complement one another. That hypothesis should be distinguished from evidence demonstrating a greater effect from the combined formulation.

Where the commercial proposition depends on a synergistic effect, the appropriate research strategy should be defined before making the claim.

Consider Probiotic and Prebiotic Combinations

Some brands want to combine probiotics with prebiotic ingredients to create a synbiotic formulation.

Probiotics are live microorganisms that confer a health benefit when administered in adequate amounts. Prebiotics are substrates selectively utilized by host microorganisms and associated with a health benefit. A synbiotic combines live microorganisms and substrates selectively utilized by host microorganisms.

A combination should be developed according to its intended purpose and supporting evidence, rather than simply adding fibre to a probiotic powder.

Select suitable prebiotic ingredients

Potential prebiotic ingredients include selected fibres and carbohydrates, such as inulin and fructooligosaccharides. Suitability depends on the intended product, target consumer, dose, regulatory status and formulation characteristics.

Ask the manufacturer to explain:

  • Why the prebiotic ingredient was selected.

  • What role it is intended to perform.

  • Whether the combination has relevant evidence.

  • How the ingredient affects moisture and powder handling.

  • Whether it changes the viable count or stability profile.

  • Whether the proposed dose is appropriate for the intended use.

Evaluate the combined formulation

A prebiotic ingredient may affect the blend's physical properties, taste, moisture behaviour or compatibility with the finished dosage form.

The combined formulation should therefore be evaluated for its intended use.

A formulation containing both probiotics and a prebiotic should not automatically be described as clinically superior to a probiotic-only product.

Separate formulation rationale from proven benefit

There may be a plausible scientific rationale for combining a particular microorganism with a particular substrate.

However, the presence of both ingredients does not, by itself, demonstrate that the finished product produces a specific health outcome.

Claims should reflect the evidence available for the formulation and comply with the relevant market's regulatory requirements.

Bifidobacterium longum probiotic powder for capsules and sachets
The dosage form shapes strain choice, formulation and stability planning.

Select the Appropriate Dosage Form

The intended dosage form should influence strain selection, formulation composition and stability planning.

A custom probiotic blend may be intended for capsules, sachets, stick packs, tablets, powders or selected functional food and beverage applications.

Each format creates distinct manufacturing considerations.

Capsules

Capsules are commonly considered for products requiring a convenient, measured serving.

The formulation team should assess:

  • Powder flow.

  • Filling consistency.

  • Moisture exposure.

  • Compatibility with capsule materials.

  • Potency per capsule.

  • Packaging protection.

  • Stability throughout shelf life.

The final capsule specification should define the required potency and applicable quality tests.

Powder sachets and stick packs

Powder formats offer flexibility for single-serving products.

Relevant considerations include:

  • Powder flow and handling.

  • Blend uniformity.

  • Filling accuracy.

  • Moisture protection.

  • Taste and dispersibility, where applicable.

  • Packaging barrier properties.

  • Stability during storage.

A powder intended for direct consumption may require different formulation characteristics from a powder intended to be incorporated into another product.

Tablets

Tablet development may introduce additional processing stresses, depending on the compression process, excipients and manufacturing conditions.

The formulation should be evaluated to establish whether the selected microorganisms can meet the required potency and stability specifications after processing.

Functional beverages

Liquid applications can present additional challenges because water activity, pH, processing temperature, preservatives and storage conditions may affect microbial survival.

A strain or blend suitable for a dry powder should not be assumed to be suitable for a beverage.

Beverage development should include appropriate compatibility and stability evaluation under the intended manufacturing and storage conditions.

Match the blend to the delivery format

The best formulation is not necessarily the one with the greatest number of strains or the highest initial potency.

It is the formulation that meets the product's scientific, technical, quality and commercial requirements in the intended delivery format.

Establish CFU Targets and Shelf-Life Requirements

CFU is a central specification in probiotic formulation.

However, a high initial CFU number does not guarantee that the finished product will maintain the required viable count throughout shelf life.

Define the potency basis

The product specification should state whether potency is expressed per gram, per capsule, per sachet, per serving or another agreed unit.

The specification should also identify the test method and the point in the product lifecycle at which the requirement applies.

Distinguish release potency from expiry potency

The release specification describes the product when it is released from manufacturing.

The end-of-shelf-life specification describes the required potency at the end of the stated shelf life under the specified storage conditions.

These values may differ because viable counts can decline during storage.

The probiotic qualification framework described by Binda and colleagues emphasizes the importance of viable microorganisms remaining present at an appropriate level throughout shelf life [4].

Develop a stability strategy

A stability programme should be appropriate to the product, packaging, storage conditions and intended shelf life.

It may include testing at defined intervals to assess whether the product continues to meet its specifications.

Relevant measurements can include viable count and other critical quality attributes identified during development.

Stability conclusions should be based on data relevant to the formulation being sold. Results from another formulation or packaging format should not automatically be treated as equivalent.

Use potency overages responsibly

A manufacturer may use an initial potency target that accounts for expected viability loss.

The approach should be supported by stability information and a documented rationale.

An arbitrary overage is not a substitute for understanding the formulation's stability characteristics.

Formulation principle: Specify the required potency at release and expiry, the test method, storage conditions and acceptance criteria before commercial production begins.

Choose Suitable Carriers and Excipients

Carriers and excipients can influence the physical properties and processing performance of probiotic blends.

Their selection should consider the formulation's intended application, compatibility, quality requirements and applicable regulations.

Functional role of carriers

Depending on the formulation, a carrier may help with powder handling, blending, filling or achieving a suitable composition.

The manufacturer should identify the carrier system and explain its purpose.

Assess excipient compatibility

The formulation team should evaluate whether excipients are suitable for the selected microorganisms and the intended manufacturing process.

Relevant considerations may include moisture behaviour, processing conditions, packaging and stability.

Review ingredient declarations

The final formulation should have a clear composition and appropriate technical documentation.

For international products, review allergen information, labeling requirements and ingredient acceptability in the destination market.

Any ingredient changes should be controlled because they may affect product performance, specifications or regulatory status.

Lactobacillus plantarum bulk probiotic powder manufacturing
Manufacturing controls and traceability keep a custom blend consistent from batch to batch.

Establish Manufacturing and Quality Requirements

Custom formulation must be supported by a manufacturing process capable of producing consistent results.

A supplier may manufacture probiotic biomass, source qualified probiotic ingredients, blend powders or perform several of these activities. The buyer should understand the supplier's actual role and quality responsibilities.

Define manufacturing responsibilities

Clarify which activities are performed in-house and which are outsourced.

These may include:

  • Strain maintenance.

  • Fermentation.

  • Harvesting and drying.

  • Ingredient sourcing.

  • Blending.

  • Packaging.

  • Laboratory testing.

  • Stability studies.

  • Batch release.

Outsourcing is not inherently a quality problem. What matters is whether the activities are performed by qualified parties under suitable controls.

Review manufacturing controls

The manufacturer should have appropriate procedures for material identification, weighing, blending, equipment cleaning, in-process checks, packaging and batch release.

The controls should be suitable for the product and manufacturing process.

Ask how the supplier investigates deviations and prevents recurrence of identified quality problems.

Assess contamination control

Probiotic production requires appropriate controls to prevent unintended microbial contamination and cross-contamination.

The supplier should explain the controls used for its facility and product, which may include equipment cleaning, segregation based on risk, personnel training, environmental monitoring where appropriate, and microbiological testing.

Buyers should request relevant documentation rather than relying solely on general statements about manufacturing quality.

Review the Certificate of Analysis

A Certificate of Analysis (CoA) should identify the tested batch and report the relevant test results.

Depending on the product, the document may include:

  • Product name and code.

  • Batch number.

  • Strain or formulation identification.

  • Viable count.

  • Relevant microbiological results.

  • Physical or chemical specifications, where applicable.

  • Test methods.

  • Release status.

  • Storage information.

The exact contents should reflect the agreed specification and applicable requirements.

Maintain traceability

The manufacturer should maintain traceability between the supplied lot, raw materials, manufacturing records, testing and release documentation.

This helps the customer investigate complaints, evaluate changes and respond to quality incidents.

Understand the Regulatory Requirements for the Intended Market

Regulatory review should be part of formulation development rather than a task postponed until the product is ready for launch.

Ingredient acceptability, product classification, permitted claims, labeling and documentation requirements vary across jurisdictions.

European Union and EFSA

The European Food Safety Authority's Qualified Presumption of Safety (QPS) framework provides a safety-assessment approach for microorganisms within its scope.

The assessment considers taxonomic identity, relevant knowledge and potential safety concerns. QPS status does not automatically authorize a finished product, and risks associated with a particular formulation or processing method may require separate consideration [7].

A strain's regulatory status should therefore be reviewed in the context of the actual ingredient, formulation and intended product category.

The manufacturer should provide available documentation, but the brand owner must ensure that the finished product complies with the relevant legal requirements.

United States

For products intended for the United States, determine the applicable requirements based on product classification, ingredient status, manufacturing controls and intended claims.

The FDA provides official information on dietary supplements and the current good manufacturing practice requirements for dietary supplements [8].

A supplier's technical documents can support the brand's review but do not automatically establish that the finished product meets every applicable requirement.

United Kingdom, India and other markets

For products intended for the United Kingdom, India, the Gulf region or other markets, review the relevant national requirements.

The review may cover:

  • Ingredient acceptability.

  • Product classification.

  • Manufacturing standards.

  • Labelling.

  • Health and nutrition claims.

  • Import documentation.

  • Product registration or notification, where applicable.

  • Country-specific restrictions.

A formulation suitable for one market should not automatically be assumed to be suitable for every destination.

Health claims and scientific substantiation

The brand's marketing claims should be consistent with the available evidence and applicable regulations.

A laboratory result does not automatically substantiate a clinical benefit. Likewise, evidence for one strain or formulation does not automatically support a claim for another.

The evidence-based review by Goodman and colleagues emphasizes the importance of evaluating the particular probiotic product and its relevant supporting evidence [3].

Where a claim is central to the product's commercial proposition, obtain an appropriate scientific and regulatory review before finalizing packaging or marketing materials.

Build an evidence dossier

For each candidate strain, maintain a structured evidence file containing:

  • Strain designation.

  • Publication details.

  • Study type.

  • Population.

  • Dose.

  • Formulation.

  • Duration.

  • Outcomes.

  • Reported limitations.

  • Relevance to the proposed product.

  • Regulatory considerations.

This dossier helps the development team make informed decisions and supports internal scientific and regulatory review.

Develop a Product-Specific Testing Plan

Testing should be planned during formulation development, not left until the first commercial batch.

The testing plan should be linked to the formulation's intended use, risks and agreed specifications.

Identity testing

Confirm that the relevant microorganisms are correctly identified using methods appropriate to the strain and product.

Potency testing

Define how viable counts will be measured and reported.

For multi-strain blends, determine whether total viable count is sufficient or whether individual strain counts are required.

A total count does not necessarily demonstrate that each strain remains present at its intended level.

Microbiological quality

Specify the relevant microbiological limits and test methods according to the product, manufacturing process and intended market.

Physical quality

Depending on the dosage form, the testing plan may include moisture-related characteristics, powder flow, blend uniformity, filling consistency or other relevant physical parameters.

Stability testing

Determine the storage conditions, test intervals, acceptance criteria and packaging system for the stability programme.

Finished-product verification

Where the ingredient will be incorporated into capsules, sachets or another finished format, assess whether additional testing is required after processing.

The ingredient's CoA alone may not establish that the final product meets its specifications after blending, filling, packaging and storage.

Build a Commercially Viable Custom Formulation

Scientific suitability is essential, but a custom blend must also be commercially practical.

The formulation team should consider the cost and complexity of each component alongside the required quality and performance.

Establish the cost structure

The total cost may include:

  • Probiotic ingredients.

  • Carriers and excipients.

  • Blending.

  • Quality-control testing.

  • Stability studies.

  • Packaging.

  • Regulatory documentation.

  • Development work.

  • Freight and storage.

  • Import duties and taxes, where applicable.

A formulation with many high-cost ingredients may not be commercially viable at the target retail price.

Balance potency and cost

A higher CFU specification may require more ingredient or a higher-potency input.

However, the potency target should be justified by the intended product specification and relevant evidence.

The formulation should not use a high CFU number solely as a marketing differentiator if the specification is unsupported by the product's purpose or commercial requirements.

Consider minimum order quantities

Custom formulations may require larger minimum order quantities than standard blends because of ingredient sourcing, production planning, testing and packaging requirements.

Ask the supplier whether it can offer development samples, pilot batches or staged production quantities.

Plan for repeat supply

Before launch, confirm whether the supplier can support the expected production volume and whether the formulation can be reproduced consistently.

For ongoing business, consider:

  • Ingredient availability.

  • Production lead times.

  • Batch consistency.

  • Change-control procedures.

  • Supply continuity.

  • Documentation updates.

  • Communication of quality issues.

A formulation that is technically successful but difficult to source consistently may create avoidable commercial risk.

Protect Formulation Ownership and Confidentiality

Custom formulation projects may involve proprietary blend compositions, product concepts, target specifications and development information.

Brands should clarify intellectual-property and confidentiality arrangements before sharing commercially sensitive information.

Questions to address include:

  • Who owns the final formulation?

  • Can the manufacturer supply the same formulation to other customers?

  • Which information is confidential?

  • Who owns development data?

  • Can the customer transfer the formulation to another manufacturer?

  • How are changes to the formulation approved?

  • What happens to technical records if the relationship ends?

The answers depend on the commercial agreement and applicable law.

Do not assume that paying for custom development automatically gives the customer exclusive ownership of every component or manufacturing method.

A written agreement can define the rights and responsibilities of both parties.

A Step-by-Step Workflow for Developing a Custom Probiotic Blend

A structured workflow reduces uncertainty and helps brands coordinate scientific, technical, regulatory and commercial decisions.

Stage 1: Define

Prepare the product brief, target consumer, intended use, dosage form, market, potency requirement, shelf life and commercial targets.

Deliverable: Approved product development brief.

Stage 2: Select

Identify candidate strains and review their identity, safety information, scientific evidence, availability and regulatory suitability.

Deliverable: Strain-selection rationale and preliminary evidence dossier.

Stage 3: Formulate

Establish the blend composition, ingredient proportions, carriers, potency target and initial specifications.

Deliverable: Draft formulation and technical specification.

Stage 4: Evaluate

Review compatibility, blend uniformity, processing suitability, microbiological quality and relevant physical characteristics.

Deliverable: Development sample and evaluation report.

Stage 5: Optimize

Refine the formulation based on test results, manufacturing requirements, cost and stability considerations.

Deliverable: Optimized formulation and updated specification.

Stage 6: Validate the production approach

Conduct appropriate pilot-scale or commercial-scale evaluation and establish the required quality controls.

Deliverable: Approved manufacturing process and testing plan.

Stage 7: Confirm stability

Generate or review suitable stability data to support the proposed packaging, storage conditions and shelf life.

Deliverable: Stability documentation and justified shelf-life specification.

Stage 8: Review regulatory readiness

Assess ingredient status, product classification, claims, labeling and documentation for each intended market.

Deliverable: Market-specific regulatory review.

Stage 9: Scale and supply

Establish production scheduling, batch-release requirements, packaging, logistics and ongoing change control.

Deliverable: Commercial supply specification and quality agreement.

The exact sequence may vary by product and market. Some activities can proceed in parallel, while others depend on earlier development results.

How to Select the Right Custom Probiotic Blend Manufacturer

The manufacturing partner can significantly influence formulation quality, project timelines and commercial success.

A suitable supplier should be able to explain its capabilities clearly and provide appropriate technical support.

Evaluate formulation expertise

Ask whether the manufacturer can support strain selection, composition development, potency calculations, dosage-form evaluation and stability planning.

Clarify which activities are performed internally and which rely on external partners.

Review scientific support

Request available publications, technical documentation and the rationale for the proposed strains.

A credible supplier should distinguish between published evidence, internal development observations and hypotheses requiring further investigation.

Assess quality systems

Review the manufacturer's quality-management arrangements, testing capabilities, batch documentation, traceability and contamination-control procedures.

Verify the scope and validity of relevant certifications.

Confirm regulatory support

Determine what technical and regulatory documents are available for the intended markets.

The supplier should not imply that one general certification or ingredient declaration automatically establishes compliance in every country.

Compare commercial terms

Compare quotations using equivalent specifications.

Review price, minimum order quantity, testing, packaging, delivery, payment terms, lead time and expected annual volume.

Use a structured scorecard

The following illustrative scorecard can help procurement teams compare suppliers.

Evaluation criterion

Suggested weighting

Strain identification and traceability

10%

Scientific evidence and formulation rationale

15%

Quality systems and manufacturing controls

15%

CFU specification and stability

15%

Technical development capability

10%

Documentation and regulatory support

10%

Commercial pricing and total cost

10%

Production capacity and lead time

5%

Supply continuity

5%

Communication and project management

5%

Total

100%

The scorecard should not replace mandatory safety, quality or regulatory requirements. A supplier that fails a critical requirement should not be approved simply because it scores well on price.

Common Mistakes in Custom Probiotic Development

Mistake 1: Choosing strains based only on popularity

A widely marketed microorganism is not necessarily the best choice for every product. Selection should reflect evidence, technical suitability and intended use.

Mistake 2: Assuming more strains means greater effectiveness

Research does not support a universal rule that multi-strain products outperform single-strain products [2].

Mistake 3: Treating species-level evidence as strain-level evidence

A study involving one strain does not automatically establish the same outcome for every strain within that species [1].

Mistake 4: Ignoring stability

A formulation may meet its initial potency specification but fail to maintain the required viable count during storage.

Mistake 5: Selecting a formulation before defining the dosage form

The processing and stability requirements for a capsule, powder sachet and beverage can differ significantly.

Mistake 6: Assuming a supplier's documentation proves regulatory compliance

Technical documentation supports the review but does not automatically establish that the finished product is compliant in every market.

Mistake 7: Making unsupported claims

Marketing claims should reflect relevant evidence and applicable regulations.

Mistake 8: Failing to plan for repeat production

The first batch may be technically successful, but the supplier must also be able to maintain the agreed specification over subsequent batches.

Mistake 9: Neglecting confidentiality

Brands should agree on formulation ownership, disclosure and reuse before beginning a commercially sensitive project.

Mistake 10: Focusing only on the purchase price

Total cost includes quality assurance, testing, packaging, logistics, regulatory work and the potential cost of inconsistent supply.

Develop Your Custom Probiotic Blend With Swiss Medicare Probiotics

Swiss Medicare Probiotics supports supplement, functional food and private-label brands with bulk probiotic strains and custom probiotic formulation. Explore our probiotic blend range, including Lactobacillus, Bifidobacterium and Bacillus strains, or contact our team to discuss your product brief.

Related Reading

Frequently Asked Questions

1. What is a custom probiotic blend?

A custom probiotic blend is a formulation developed or adapted to meet defined product requirements. It may involve selecting specific strains, determining their proportions, establishing a CFU specification, choosing carriers, evaluating stability and preparing documentation for the intended application.

Custom formulation can help a brand align its product composition, dosage form, potency, packaging and target-market requirements with a defined commercial objective. However, customization alone does not prove that a product is more effective than an existing formulation.

Not automatically. A standard blend may be suitable if it meets the product requirements and has appropriate documentation. A custom blend is valuable when the project requires a specific composition, specification or technical approach that an existing product does not adequately meet.

There is no universal ideal number. The number should follow the formulation rationale, evidence, compatibility, stability, quality requirements and commercial constraints. Research does not establish that increasing the number of strains automatically improves effectiveness [2].

Start with the intended product objective and review strain identity, safety information, scientific evidence, dose, stability, manufacturing suitability and regulatory status. Evidence should be relevant to the particular strain and intended application [3].

Potentially, yes. The proposed combination should be evaluated for its scientific rationale, compatibility, stability, manufacturing suitability and regulatory requirements. The fact that individual ingredients are available does not automatically establish that every combination is suitable.

Yes, where the ingredients are suitable for the intended product and market. The combined formulation should be evaluated for composition, compatibility, stability, processing and labeling requirements. Any health-related claims must be supported by relevant evidence and comply with applicable regulations.

CFU stands for colony-forming units, a measure of viable microorganisms capable of forming colonies under specified test conditions. The specification should clearly state whether the CFU value applies per gram, per serving or to another defined unit.

The specification should clearly identify the required potency at release and, where applicable, the minimum viable count guaranteed at the end of shelf life. Stability data should support the proposed shelf-life specification [4].

The timeline depends on formulation complexity, ingredient availability, sample evaluation, testing requirements, stability studies, regulatory review and production scale-up. Request a project plan that identifies the expected duration and deliverables for each stage.

Potentially, but the formulation may require different evaluations for each dosage form. Powder flow, moisture exposure, filling conditions, packaging and stability should be considered before the blend is approved for commercial production.

Depending on the product and market, relevant documents may include a Certificate of Analysis, product specification, technical data sheet, strain identity information, safety documentation, microbiological test results, stability data, storage instructions and regulatory declarations.

Search PubMed and Europe PMC using the full strain designation and intended application. Examine the study design, population, dose, formulation, outcomes and limitations. ClinicalTrials.gov can help identify registered studies, but registration alone does not establish effectiveness [8].

No. QPS is a safety-assessment framework for microorganisms within its scope. It does not automatically authorize a finished product, and additional requirements may apply to the ingredient, formulation and product category [7].

Not automatically. Evidence for individual strains does not necessarily establish the effectiveness of the complete blend. Claims should reflect the evidence relevant to the final formulation and comply with the applicable market's regulations.

A probiotic manufacturer may produce microbial biomass or probiotic powders, while a blender combines qualified ingredients into a specified formulation. Some suppliers perform both activities. Buyers should confirm the actual manufacturing scope and quality responsibilities.

Shelf life may be influenced by the microorganisms, formulation, moisture, oxygen exposure, temperature, packaging and storage conditions. The appropriate shelf-life specification should be supported by relevant stability data.

Discuss confidentiality, formulation ownership, permitted reuse, development data, transfer rights and change control before sharing sensitive information. The commercial agreement should clearly define the rights and responsibilities of both parties.

Compare equivalent specifications, including strain composition, potency, testing, documentation, packaging, shelf life, MOQ, lead time, delivery terms and payment conditions. A lower price is not necessarily better value if the supplied material fails to meet the required specification.

Swiss Medicare Probiotics can discuss relevant bulk probiotic ingredient, custom formulation and manufacturing requirements with B2B customers, subject to the capabilities and services available for each project. Prospective customers should provide their intended application, target market, dosage form, potency requirements, estimated volume and documentation needs so that technical feasibility can be assessed. Contact our team to start the conversation.

Scientific References

The following references correspond to the numbered citations used throughout the article.

[1] McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Frontiers in Medicine. 2018. PubMed | Full text on PubMed Central

[2] McFarland LV. Efficacy of Single-Strain Probiotics Versus Multi-Strain Mixtures: Systematic Review of Strain and Disease Specificity. Digestive Diseases and Sciences. 2021;66:694–704. PubMed

[3] Goodman C, Keating G, Georgousopoulou E, et al. Choosing an Appropriate Probiotic Product for Your Patient: An Evidence-Based Practical Guide. PubMed | Full text on PubMed Central

[4] Binda S, Hill C, Johansen E, et al. Criteria to Qualify Microorganisms as “Probiotic” in Foods and Dietary Supplements. Frontiers in Microbiology. 2020;11:1662. PubMed | Full text on PubMed Central

[5] National Institutes of Health, Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals. Official NIH resource

[6] Effectiveness of Multistrain Versus Single-strain Probiotics: Current Status and Recommendations for the Future. PubMed

[7] European Food Safety Authority (EFSA). Qualified Presumption of Safety (QPS). Official EFSA topic page | EFSA QPS assessment information

[8] U.S. Food and Drug Administration. Dietary Supplements. FDA | Global Analysis of Clinical Trials with Probiotics. Full text on PubMed Central

 
 
 

Comments


bottom of page